Celularity regains NASDAQ compliance after filing delayed annual report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St falls as Trump's Iran remarks rattle investors; Broadcom gains
- Oil prices jump 7% as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
May 1, 2026 4:30 PM EDTCompany advances focused strategy, strengthens balance sheet and positions business for long-term growth
FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity or the Company), a longevity-focused regenerative and cellular medicine company, today announced that it has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission.
As previously disclosed, on April 16, 2026, the Company received a notification from the... More
